Nuss Procedure: Clinical Options in Pediatric Pain Management?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients undergoing the NUSS procedure since the beginning of 2011 to Sept. 30th, 2013.
Exclusion Criteria:
- None
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patient controlled analgesia
Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
|
A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
|
|
Continuous thoracic epidural infusion
Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
|
Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.
|
|
Continuous paravertebral blockade
Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
|
Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total morphine dose
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days
|
Total morphine dose will be evaluated in mg/kg/24 hour period, beginning with post-op day 0 until discharge from the hospital.
|
Participants will be followed for the duration of hospital stay, an expected average of 3 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain score
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days
|
Pain scores obtained from the visual analog scale.
|
Participants will be followed for the duration of hospital stay, an expected average of 3 days
|
|
Length of hospitalization
Time Frame: Within the first week after surgery.
|
Determine if there is a difference in length of hospitalization, and time to discharge.
|
Within the first week after surgery.
|
|
Nausea and vomiting
Time Frame: 0-48 hrs. post-op
|
Determine the incidence of nausea and vomiting measured by the postoperative ondansetron dosing, beginning with arrival to floor and up to the first 48 hrs of hospitalization.
|
0-48 hrs. post-op
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Beltran Ralph, MD, Nationwide Children's Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB13-00702
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.